In Bram Stoker's 1897 novel, Lucy Westenra is dying by inches, drained night after night by a vampire she cannot name. The men who love her respond the only way nineteenth-century medicine allows: they give her their own blood, one after another — Arthur, then Seward, then Van Helsing, then Quincey — each convinced that the simple physical act of putting more blood into her veins will restore what has been taken from her. It doesn't work. Lucy dies and returns as one of the undead anyway, and Stoker never quite explains the failure beyond the vampire's supernatural advantage. There is a plainer explanation sitting in the novel's blind spot: Dracula was published in 1897, four years before Karl Landsteiner described the ABO blood group system. Every transfusion in the book is a coin flip the characters didn't know they were making.

I open with this because platelet-rich plasma (PRP) — popularly nicknamed the "vampire facial" for the syringe-and-blood-draw theater of the procedure — inherits both halves of that scene: the same old hope that blood itself carries something restorative, and a real biological answer to a question Stoker's doctors couldn't have known to ask. PRP works, when it works, for a reason that has nothing to do with donated vitality and everything to do with concentrating a patient's own platelets and returning them to that same patient's skin.

What's Actually in the Syringe

PRP is not blood magic transferred from a donor; it is autologous — drawn from the patient, centrifuged to separate and concentrate the platelet fraction, then reinjected into the same patient's face. A 2024 review by Vladulescu et al. in Biomedicines lays out the mechanism in granular detail: once platelets are activated, their alpha granules begin releasing growth factors within about ten minutes, with at least 95% released within the first hour — a payload that includes platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), insulin-like growth factor-1, fibroblast growth factor, and hepatocyte growth factor. TGF-β1 specifically increases type I collagen production while suppressing its breakdown; PDGF and VEGF drive revascularization of the treated tissue; fibroblast growth factor and TGF-β together activate fibroblasts toward tissue renewal. None of this requires anyone else's blood. It requires only that the patient's own platelets be concentrated enough, and delivered precisely enough, to trigger a repair cascade the skin already knows how to run.

The Problem Stoker's Century Couldn't See

The detail worth sitting with is that Lucy's transfusions weren't just futile against a vampire — by modern standards, they were dangerous regardless of the vampire. Four different men's blood, given with no knowledge of blood-type compatibility, carried a real risk of acute hemolytic transfusion reaction, the same mismatch risk that transfusion medicine now screens against as a matter of routine, using a test that didn't exist yet when Stoker was writing. PRP sidesteps that entire category of risk by design, not by luck: because the blood being reinjected is the patient's own, there is no compatibility question to get right or wrong. This is also, not incidentally, why PRP's safety profile across the literature is consistently mild — injection-site pain, transient redness, swelling — rather than the systemic risks associated with allogeneic blood products.

What the Trials Actually Show

The best-studied region for PRP's cosmetic use is, fittingly, the area a dying patient's own doctors would have watched most closely: the periorbital zone. Evans et al. (2021), in a systematic review and meta-analysis in Archives of Dermatological Research, pooled nineteen studies covering 455 patients (95% female, ages 28 to 60) across three outcome categories — fine lines, pigmentation, and general photoaging — with patients typically receiving about three treatments spaced roughly 23 days apart and followed for about three months. Meta-analysis of the three studies with a randomized, controlled design found a statistically significant increase in patient-reported satisfaction over controls (p = .001), alongside blinded evaluator assessments and, in some included studies, histologic evidence of improvement. This is a real, measured, reasonably consistent effect — modest, not miraculous, and dependent on a course of multiple sessions rather than a single draw of blood.

The Honest Caveat

Zooming out from the periorbital-specific data to skin aging more broadly, a 2025 meta-analysis by Chen and Zhou in Aesthetic Surgery Journal Open Forum, pooling nine randomized controlled trials and 358 patients, found PRP outperformed controls on both subjective satisfaction (risk ratio 1.34) and objective evaluator ratings (risk ratio 1.42), with no significant difference in adverse events. That is a genuinely encouraging summary number. It should be read next to a more skeptical one: Cruciani et al. (2024), publishing an umbrella review of the entire systematic-review literature in Blood Transfusion, found thirteen systematic reviews built on only 28 primary studies — eighteen of them uncontrolled — and rated twelve of those thirteen reviews as critically low or low quality by AMSTAR-2 criteria. Their conclusion was blunt: the evidence is "insufficient to suggest firm conclusions" about PRP's efficacy for facial rejuvenation, even as they confirmed that reported adverse events, where reported at all, were limited to mild, transient effects with no documented serious harm or infection.

Stoker's characters believed, wrongly and dangerously, that blood itself was interchangeable — that whose vein it came from mattered less than the act of giving it. The actual science of platelet-rich plasma inverts that belief, and only works because it does: the source has to be the same person the syringe returns to, and the effect is real but proportionate — a measurable, growth-factor-driven improvement in skin quality that shows up reliably across trials, wrapped in a body of evidence that is still, honestly, thinner and more heterogeneous than the "vampire facial" nickname implies. Lucy Westenra needed a transfusion medicine that didn't exist yet. What she didn't need, and what nobody getting PRP today needs either, is anyone else's blood at all.

References

Chen, H., & Zhou, X. (2025). Meta-analysis of the efficacy of platelet-rich plasma in treating skin aging. Aesthetic Surgery Journal Open Forum, 8, ojaf150. https://doi.org/10.1093/asjof/ojaf150

Cruciani, M., Masiello, F., Pati, I., Pupella, S., & De Angelis, V. (2024). Platelet-rich plasma for facial rejuvenation: An overview of systematic reviews. Blood Transfusion, 22(5), 429–440. https://doi.org/10.2450/BloodTransfus.730

Evans, A. G., Ivanic, M. G., Botros, M. A., Pope, R. W., Halle, B. R., Glassman, G. E., Genova, R., & Al Kassis, S. (2021). Rejuvenating the periorbital area using platelet-rich plasma: A systematic review and meta-analysis. Archives of Dermatological Research, 313(9), 711–727. https://doi.org/10.1007/s00403-020-02173-z

Vladulescu, D., Scurtu, L. G., Simionescu, A. A., Scurtu, F., Popescu, M. I., & Simionescu, O. (2024). Platelet-rich plasma (PRP) in dermatology: Cellular and molecular mechanisms of action. Biomedicines, 12(1), 7. https://doi.org/10.3390/biomedicines12010007